Cardinal Drug Profile
Key Indicators
- Authorised Capital ₹ 6.60 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.98 Cr
as on 24-10-2024
- Company Age 31 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.10 Cr
as on 24-10-2024
- Satisfied Charges ₹ 8.50 Cr
as on 24-10-2024
- Revenue 175.30%
(FY 2023)
- Profit -878.48%
(FY 2023)
- Ebitda -689.48%
(FY 2023)
- Net Worth -2.54%
(FY 2023)
- Total Assets 0.49%
(FY 2023)
About Cardinal Drug
The Corporate was formerly known as Gwalior Fluorochem Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.60 Cr and a paid-up capital of Rs 4.98 Cr.
The company currently has active open charges totaling ₹13.10 Cr. The company has closed loans amounting to ₹8.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anil Somani, Sunil Kala, and Geetika Somani serve as directors at the Company.
- CIN/LLPIN
U24114MP1993PLC007463
- Company No.
007463
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Jan 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Gwalior, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Cardinal Drug?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Somani  | Director | 14-Jan-1993 | Current |
| Sunil Kala | Director | 01-Sep-1993 | Current |
| Geetika Somani | Director | 14-Jan-1993 | Current |
Financial Performance and Corporate Structure Insights of Cardinal Drug.
Cardinal Drug Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 175.3% increase. The company also saw a substantial fall in profitability, with a 878.48% decrease in profit. The company's net worth dipped by a decrease of 2.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cardinal Drug?
In 2023, Cardinal Drug had a promoter holding of 87.60% and a public holding of 12.40%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fostiima Integrated Learning Resources Private LimitedActive 14 years 9 monthsAnil Somani and Sunil Kala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 01 May 1997 | ₹7.60 Cr | Open |
State Bank Of India Creation Date: 29 Jan 1997 | ₹4.60 Cr | Open |
M. P. Financial Corporation Creation Date: 08 Jan 1997 | ₹9.00 M | Open |
How Many Employees Work at Cardinal Drug?
Unlock and access historical data on people associated with Cardinal Drug, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cardinal Drug, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cardinal Drug's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
